Table 6.
Summary of the axonal parameters considering circuitry context.
| T3− | LD × HD | T3+ | LD × HD | T3− × T3+ | |||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± sem | n | P# | P° | Mean ± sem | n | P# | P° | P* | |
| AXON LENGTH | |||||||||
| LD fields (μm/field) | |||||||||
| Control | 938 ± 54 | 33 | 577 ± 53 | 36 | <0.001 | ||||
| BDNF | 935 ± 52 | 38 | 0.734 | 561 ± 46 | 37 | 0.812 | <0.001 | ||
| K252a | 871 ± 120 | 15 | 0.306 | 923 ± 126 | 7 | 0.022 | 0.573 | ||
| Rapamycin | 589 ± 41 | 23 | <0.001 | 340 ± 43 | 24 | 0.002 | <0.001 | ||
| <0.001 | <0.001 | ||||||||
| HD fields (μm/field) | |||||||||
| Control | 966 ± 59 | 27 | 0.941 | 921 ± 43 | 24 | <0.001 | 0.671 | ||
| BDNF | 1094 ± 69 | 22 | 0.181 | 0.071 | 1084 ± 45 | 23 | 0.012 | <0.001 | 0.829 |
| K252a | 1070 ± 52 | 45 | 0.143 | 0.052 | 945 ± 40 | 53 | 0.506 | 0.800 | 0.125 |
| Rapamycin | 729 ± 35 | 37 | 0.001 | 0.064 | 813 ± 45 | 36 | 0.108 | <0.001 | 0.129 |
| <0.001 | 0.003 | ||||||||
| GABA BOUTONS | |||||||||
| LD fields (counts/field) | |||||||||
| Control | 44 ± 4 | 33 | 48 ± 6 | 36 | 0.843 | ||||
| BDNF | 60 ± 4 | 38 | 0.014 | 43 ± 4 | 37 | 0.808 | 0.004 | ||
| K252a | 47 ± 6 | 15 | 0.815 | 78 ± 9 | 7 | 0.009 | 0.020 | ||
| Rapamycin | 48 ± 4 | 23 | 0.351 | 35 ± 4 | 24 | 0.141 | 0.015 | ||
| 0.036 | 0.006 | ||||||||
| HD fields (counts/field) | |||||||||
| Control | 51 ± 3 | 27 | 0.181 | 88 ± 6 | 24 | <0.001 | <0.001 | ||
| BDNF | 79 ± 4 | 22 | <0.001 | 0.001 | 123 ± 5 | 23 | <0.001 | <0.001 | <0.001 |
| K252a | 62 ± 3 | 45 | 0.025 | 0.026 | 84 ± 4 | 53 | 0.813 | 0.549 | <0.001 |
| Rapamycin | 66 ± 3 | 37 | 0.004 | 0.001 | 104 ± 7 | 36 | 0.124 | <0.001 | <0.001 |
| <0.001 | <0.001 | ||||||||
| MW-RST ANOVA | MW-RST ANOVA | ||||||||
P#, P-value of drug treatment groups vs. untreated controls of the same hormone category; P*, P-value of T3+ vs. T3− of the same drug category; P°, P-values of LD vs. HD of the same drug category. Statistical tests as in Table 1. n, number of fields.